ClinicalTrials.gg
CompletedNCT02171598Updated Jun 24, 2014

Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects

A Phase 1 interventional study of Clopidogrel and Dabigatran high dose in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Male
01

Study summary

The primary objective of the study (Main Part 2) was to investigate whether and to which extent a combination of multiple oral doses (steady state conditions) of 75 mg of clopidogrel q.d. (after a loading dose of 300 mg) and multiple doses of 150 mg of dabigatran etexilate b.i.d. at steady state affects pharmacokinetic and pharmacodynamic parameters of dabigatran etexilate and clopidogrel.

The objective of the preceding Pilot Part 1 of the study was to explore the effect of a single dose of 300 mg clopidogrel administered after multiple doses of 75 mg and 150 mg dabigatran had reached steady state, regarding safety as well as pharmacokinetic and pharmacodynamic parameters.

The Main Part 3 of the study moreover was to compare intra-individually the effects of a single dose of 600 mg clopidogrel with the same dose, 600 mg clopidogrel, given additionally to multiple doses of 150 mg dabigatran in steady state condition with respect to safety and pharmacokinetic and pharmacodynamic parameters.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the following criteria: Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate), body temperature, 12-lead , clinical laboratory tests
  2. Age ≥18 and Age ≤40 years
  3. (BMI) ≥18.5 and ≤29.9 kg/m2 (Body Mass Index)
  4. Signed and dated written prior to admission to the study in accordance with GCP and the local legislation.

Exclusion criteria

Exclusion Criteria:

  1. Any gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Subjects who in the investigator's judgement are perceived as having an increased risk of bleeding, for example because of:

    • Hemorrhagic disorders or bleeding diathesis
    • Occult blood in faeces or haematuria
    • Trauma or surgery within the last month or as long as an excessive risk of bleeding persists after these events, or planned surgery during trial participation
    • History of arteriovenous malformation or aneurysm
    • History of gastroduodenal ulcer disease, gastrointestinal haemorrhage and haemorrhoids
    • History of intracranial, intraocular, spinal, retroperitoneal, or atraumatic intraarticular bleeding
    • Use of drugs that may interfere with haemostasis during trial conduct (e.g.acetyl salicylic acid or other non-steroidal anti-inflammatory drugs)
  3. Relevant surgery of gastrointestinal tract
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of allergy/ (including drug allergy) which is deemed relevant to the trial as judged by the investigator
  8. Intake of any medication within four weeks of first dosing
  9. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within four weeks prior to administration or during the trial, especially inhibitors or inducers of P-gp, CYP2C9 or CYP2C19
  10. Intake of medication, which influences the blood clotting, i.e., acetylsalicylic acid, nonsteroidal anti-rheumatic drugs, cumarin etc. within 10 days prior to administration or during the trial
  11. Participation in another trial with an drug within one month prior to administration or during the trial
  12. Alcohol abuse (more than 60 g/day on a regular basis)
  13. Drug abuse
  14. Within 5 days of study medication no intake of grapefruit, grapefruit juice, or products containing grapefruit juice, Seville oranges, garlic supplements, or St. John's Worth
  15. Blood donation (more than 100 mL within four weeks prior to administration)
  16. Excessive physical activities (within one week prior to administration or during the trial)
  17. Any laboratory value outside the reference range that is of clinical relevance
  18. Inability to comply with dietary regimen of study centre
  19. Male subjects do not agree to minimise the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the study. Acceptable methods of comprises barrier contraception and a medically accepted contraceptive method for the female partner (intra-uterine device with spermicide, hormonal contraceptive since at least two months)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Fixed sequence 1

    multiple-dose, fixed-sequence with 2 periods of 4 days separated by a washout period of at least 14 days. A single dose of 300 mg clopidogrel will be given on top of 75 mg or 150 mg dabigatran in steady state.

    Drug: Clopidogrel · Drug: Dabigatran high dose · Drug: Dabigatran low dose

  • Experimental
    Crossover

    clopidogrel + dabigatran / clopidogrel / dabigatran in randomized order

    Drug: Clopidogrel · Drug: Dabigatran high dose · Drug: Dabigatran low dose

  • Experimental
    Fixed sequence 2

    intra-individual comparison with the fixed sequence of a single dose of 600mg clopidogrel alone and the combination of dabigatran 150 mg in steady state plus single dose of 600 mg clopidogrel

    Drug: Clopidogrel · Drug: Dabigatran high dose

Interventions

  • DrugDabigatran high dose
  • DrugDabigatran low dose
06

What researchers measure

Primary outcomes

  1. AUCτ,ss (area under the concentration-time curve of the analyte in plasma over one dosing interval at steady state)

    for total dabigatran, clopidogrel and the inactive metabolite SR26334

    Time frame: up to 19 days

  2. AUC0-24,1 (area under the concentration-time curve of the analyte in plasma over one dosing interval after the loading dose)

    for clopidogrel and the inactive metabolite SR26334

    Time frame: up to 19 days

  3. Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)

    for total dabigatran, clopidogrel and the inactive metabolite SR26334

    Time frame: up to 19 days

  4. Cmax,1 (maximum measured concentration of the analyte in plasma after the loading dose)

    for total dabigatran, clopidogrel and the inactive metabolite SR26334

    Time frame: up to 19 days

  5. AUECIPA,0-24 (area under the effect curve of inhibition of platelet aggregation after the first dose of clopidogrel)

    Time frame: up to 19 days

  6. Emax,IPA,0-24 (maximum percentage change - compared to baseline - in adenosine diphosphate-induced platelet aggregation after the loading dose of clopidogrel)

    Time frame: baseline, up to 19 days

Secondary outcomes

  1. tmax (time from dosing to the maximum concentration of the analyte in plasma)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  2. AUC0-infinity (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  3. AUC0-tz (area under the concentration-time curve of the analyte in plasma from the time point 0 to the last quantifiable analyte plasma concentration)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  4. λz (terminal rate constant in plasma)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  5. t1/2 (terminal half-life of the analyte in plasma)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  6. MRTpo (mean residence time of the analyte in the body after oral administration)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  7. CL/F (apparent clearance of the analyte in the plasma after extravascular administration)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  8. Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)

    Clopidogrel and SR 26334 after the loading dose

    Time frame: up to 8 weeks

  9. Cmax, ss

    free dabigatran after multiple dosing

    Time frame: up to 8 weeks

  10. AUCτ,ss

    free dabigatran after multiple dosing

    Time frame: up to 8 weeks

  11. AUC0-tz,ss (area under the concentration-time curve of the analyte in plasma from the time point 0 after the last dose at steady state to the last quantifiable analyte plasma concentration within the uniform dosing interval τ)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  12. tz,ss (time of last measureable concentration of the analyte in plasma within the dosing interval τ at steady state)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  13. tmax,ss (time from last dosing to the maximum concentration of the analyte in plasma at steady state on day 4)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  14. CL/F,ss (apparent clearance of the analyte in the plasma at steady state after extravascular multiple dose administration)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  15. Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  16. tmin,ss (time from last dosing to the minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  17. Cpre,ss (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  18. MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  19. Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following an extravascular administration)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  20. PTF (peak trough fluctuation)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  21. Cavg (average concentration of the analyte in plasma at steady state over a uniform dosing interval)

    Clopidogrel and SR 26334; dabigatran (free and total) after multiple dosing

    Time frame: up to 8 weeks

  22. AUECt1-t2 (area under the effect curve (baseline corrected by ratio))

    for activated partial thromboplastin time, thrombin time and ecarin clotting time

    Time frame: up to 8 weeks

  23. ERmax (maximum effect ratio)

    for activated partial thromboplastin time, thrombin time and ecarin clotting time

    Time frame: up to 8 weeks

  24. tmax (time to maximum effect)

    for activated partial thromboplastin time, thrombin time and ecarin clotting time

    Time frame: up to 8 weeks

  25. Occurence of Adverse Events

    Time frame: up to 13 weeks

  26. Assessment of Tolerability by investigator

    Time frame: up to 13 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009 and a primary completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Feb 2009
Primary completionActual
Jul 2009
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02171598
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Feb 2009
Primary completion
Jul 2009
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clopidogrel

Start the discussion